Episode Details

Bristol Myers Squibb and Johnson & Johnson face stark contrasts in strategy, scale, and risk. Bristol Myers, a focused cancer and immune disease specialist, posted $48 billion in revenue and $7 billion profit, though burdened by debt and facing drug pricing pressures. Johnson & Johnson, a diversified health giant, crushed it with $94 billion revenue and $27 billion profit, boasting a healthy margin and minimal debt—but still reeling from talc lawsuits and competition for Stelara. For 2026, Bristol Myers looks undervalued and promising with a strong pipeline, while Johnson & Johnson’s legal and market headwinds make it a riskier bet.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/b37cb664708c7761